Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Riluzole Combination Therapy for Moderate-To-Severe Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial Publisher Pubmed



Salardini E1 ; Zeinoddini A1 ; Mohammadinejad P1 ; Khodaieardakani MR2 ; Zahraei N1 ; Zeinoddini A1 ; Akhondzadeh S1
Authors
Show Affiliations
Authors Affiliations
  1. 1. Psychiatric Research Center, Roozbeh Hospital, Tehran University of Medical Sciences, Tehran, Iran
  2. 2. Razi Hospital, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran

Source: Journal of Psychiatric Research Published:2016


Abstract

Recent evidences suggest that glutamatergic dysregulation implicated in neural plasticity and cellular resilience may contribute to the pathophysiology of Major Depressive Disorder (MDD). Riluzole, which exerts its effect by targeting glutamate neurotransmission, has shown antidepressant effect in recent preclinical, observational and open label studies. This study aimed to assess the efficacy and tolerability of riluzole in patients with MDD. Sixty-four inpatients with diagnosis of moderate to severe major depressive disorder participated in a parallel, randomized, controlled trial, and sixty patients underwent 6 weeks treatment with either riluzole (50 mg/bid) plus citalopram (40 mg/day) or placebo plus citalopram (40 mg/day). All participants were inpatients for the whole duration of the study. Patients were assessed using Hamilton depression rating scale (HDRS) at baseline and weeks 2, 4 and 6. The primary outcome measure was to assess the efficacy of riluzole compared to placebo in improving the depressive symptoms. General linear model repeated measures demonstrated significant effect for time × treatment interaction on HDRS [F (1.86, 107.82) = 8.63, p < 0.001]. Significantly greater improvement was observed in HDRS scores in the riluzole group compared to the placebo group from baseline HDRS score at weeks 2, 4 and 6 (p < 0.001, p = 0.001, p = 0.002, respectively). Significantly greater response with greater speed to treatment was observed in the riluzole group than the placebo group. No serious adverse event occurred. This study showed a favorable safety and efficacy profile in patients with major depressive disorder. Larger controlled studies with longer treatment periods are needed to investigate long term safety, efficacy and optimal dosing. © 2016 Elsevier Ltd.
Related Docs
View other Related Docs
1. Effect of Memantine Combination Therapy on Symptoms in Patients With Moderate-To-Severe Depressive Disorder: Randomized, Double-Blind, Placebo-Controlled Study, Journal of Clinical Pharmacy and Therapeutics (2017)
2. L-Carnosine Combination Therapy for Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial, Journal of Affective Disorders (2020)
3. Efficacy and Safety of Celecoxib Monotherapy for Mild to Moderate Depression in Patients With Colorectal Cancer: A Randomized Double-Blind, Placebo Controlled Trial, Psychiatry Research (2017)
4. Riluzole for Treatment of Men With Methamphetamine Dependence: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial, Journal of Psychopharmacology (2019)
5. Duloxetine Add-On to Risperidone for Treatment of Negative Symptoms in Patients With Stable Schizophrenia: Randomized Double-Blind Placebo-Controlled Study, Pharmacopsychiatry (2016)
6. Comparison of Saffron Versus Fluoxetine in Treatment of Mild to Moderate Postpartum Depression: A Double-Blind, Randomized Clinical Trial, Pharmacopsychiatry (2017)
7. Citicoline Combination Therapy for Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial, Clinical Neuropharmacology (2017)
8. Ketamine and Other Glutamate Receptor Modulating Agents for Treatment-Resistant Depression: A Systematic Review of Randomized Controlled Trials, Iranian Journal of Psychiatry (2022)
Experts (# of related papers)
View all Related Experts
Shahin Akhondzadeh Basti (29)
Somaye Arabzadeh (4)
Other Related Docs
9. Therapeutic Effects of Minocycline on Mild-To-Moderate Depression in Hiv Patients: A Double-Blind, Placebo-Controlled, Randomized Trial, International Clinical Psychopharmacology (2016)
10. Monoclonal Antibody a Promising Treatment for Depression, Avicenna Journal of Medical Biotechnology (2019)
11. Celecoxib Versus Diclofenac in Mild to Moderate Depression Management Among Breast Cancer Patients: A Double-Blind, Placebo-Controlled, Randomized Trial, Annals of Pharmacotherapy (2015)
12. A Randomized, Double-Blind Placebo-Controlled Trial on Effectiveness and Safety of Celecoxib Adjunctive Therapy in Adolescents With Acute Bipolar Mania, Journal of Child and Adolescent Psychopharmacology (2017)
13. The Effects of Pioglitazone Adjuvant Therapy on Negative Symptoms of Patients With Chronic Schizophrenia: A Double-Blind and Placebo-Controlled Trial, Human Psychopharmacology (2016)
14. Cilostazol As an Adjunctive Treatment in Major Depressive Disorder: A Pilot Randomized, Double-Blind, and Placebo-Controlled Clinical Trial, Psychopharmacology (2022)
15. Fabrication of a Controlled-Release Core-Shell Floating Tablet of Ketamine Hydrochloride Using a 3D Printing Technique for Management of Refractory Depressions and Chronic Pain, Polymers (2024)
16. Evidence for Anti-Inflammatory Effects of Adalimumab in Treatment of Patients With Major Depressive Disorder: A Pilot, Randomized, Controlled Trial, Clinical Neuropharmacology (2022)
17. Depression and Inflammation: Is There Any Role for Biomarkers?, Avicenna Journal of Medical Biotechnology (2019)
18. Pioglitazone Adjunctive Therapy for Depressive Episode of Bipolar Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial, Depression and Anxiety (2015)
19. Riluzole in Augmentation of Fluvoxamine for Moderate to Severe Obsessive–Compulsive Disorder: Randomized, Double-Blind, Placebo-Controlled Study, Psychiatry and Clinical Neurosciences (2016)
20. Efficacy and Safety of Celecoxib Monotherapy for Treatment of Moderate Depressive Symptoms Following Covid-19 Infection: A Randomized, Double-Blind, Placebo-Controlled Trial, Journal of Psychosomatic Research (2023)
21. L-Theanine Combination Therapy With Fluvoxamine in Moderate-To-Severe Obsessive–Compulsive Disorder: A Placebo-Controlled, Double-Blind, Randomized Trial, Psychiatry and Clinical Neurosciences (2023)
22. Does Oral Administration of Ketamine Accelerate Response to Treatment in Major Depressive Disorder? Results of a Double-Blind Controlled Trial, Journal of Affective Disorders (2018)
23. Efficacy and Safety of Celecoxib for Treatment of Mild to Moderate Postpartum Depression: A Randomized, Double-Blind, Placebo-Controlled Trial, Archives of Gynecology and Obstetrics (2024)
24. Acetaminophen As Adjuvant to Risperidone in Chronic Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial, Iranian Journal of Psychiatry (2018)
25. Agmatine Enhances the Antidepressant-Like Effect of Lithium in Mouse Forced Swimming Test Through Nmda Pathway, Biomedicine and Pharmacotherapy (2017)
26. Celecoxib in Treatment of Postpartum Depression: A Case Report, Archives of Iranian Medicine (2023)
27. Risperidone Combination Therapy With Propentofylline for Treatment of Irritability in Autism Spectrum Disorders: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial, Clinical Neuropharmacology (2019)
28. Celecoxib for the Treatment of Mild-To-Moderate Depression Due to Acute Brucellosis: A Double-Blind, Placebo-Controlled, Randomized Trial, Journal of Clinical Pharmacy and Therapeutics (2015)
29. Fluvoxamine Combination Therapy With Tropisetron for Obsessive-Compulsive Disorder Patients: A Placebo-Controlled, Randomized Clinical Trial, Journal of Psychopharmacology (2019)
30. Simvastatin Versus Atorvastatin for Improving Mild to Moderate Depression in Post-Coronary Artery Bypass Graft Patients: A Double-Blind, Placebo-Controlled, Randomized Trial, Journal of Affective Disorders (2015)
31. Simvastatin As an Adjuvant Therapy to Fluoxetine in Patients With Moderate to Severe Major Depression: A Double-Blind Placebo-Controlled Trial, Journal of Psychopharmacology (2015)